DUBLIN, May 1, 2024 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that Company management will participate in the BofA Securities 2024 Global Health Care Conference on Wednesday, May 15, 2024, in Las Vegas. The fireside chat will be held at 10:00 a.m. PT / 1:00 p.m. ET / 6:00 p.m. IST.   An audio webcast of the fireside chat will be available via the Investors section of the Jazz Pharmaceuticals website at https://investor.jazzpharma.com/investors/events-presentations. A replay of ...

Exhibit 99.1 Jazz Pharmaceuticals Announces First Quarter 2024 Financial Results and Affirms 2024 Financial Guidance – 12% year-over-year revenue increase from combined key growth drivers: Xywav , Epidiolex and Rylaze – – Oncology revenues grew 13% year-over-year – – Submitted zanidatamab BLA for 2L BTC; expect to launch in 2025 or earlier – – Top-line Phase 2b data from suvecaltamide trial in essential tremor expected in late 1H24 – – 2024 total revenue guidance affirmed at $4.0 to $4.2 billion – ® ® ® Bus ...

Wall Street expects a year-over-year increase in earnings on higher revenues when Jazz Pharmaceuticals (JAZZ) reports results for the quarter ended March 2024. While this widely-known consensus outlook is important in gauging the company's earnings picture, a powerful factor that could impact its near-term stock price is how the actual results compare to these estimates.The stock might move higher if these key numbers top expectations in the upcoming earnings report, which is expected to be released on May ...

Two oral presentations share results of real-world impact of idiopathic hypersomnia and long-term effectiveness of Epidiolex® (cannabidiol) in treatment-resistant epilepsies Thirteen abstracts underscore Jazz's diverse neuroscience portfolio and pioneering efforts to continue advancing the treatment of serious sleep disorders, rare epilepsy syndromes and movement disorders DUBLIN, April 10, 2024 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that 13 abstracts from across its neurosc ...

Submission based on data from Phase 2b HERIZON-BTC-01 trial, which met its primary endpoint in patients receiving zanidatamab for previously treated HER2-positive biliary tract cancer (BTC) Confirmatory Phase 3 trial in first-line (1L) BTC open for enrollment at multiple global sites DUBLIN, April 2, 2024 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the company has completed the rolling submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administrat ...

DUBLIN, March 12, 2024 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) will host a virtual R&D Day, Tuesday, March 19, from 8:00 a.m. to 10:00 a.m. ET, focused on zanidatamab, a differentiated, bispecific antibody in late-stage development with the potential to transform the standard of care in multiple HER2-positive cancers. The webcast will highlight the mechanistic rationale and clinical data that support further development of zanidatamab as a treatment for biliary tract cancer (BTC), gastroesop ...

Jazz Pharmaceuticals (JAZZ) reported adjusted earnings of $5.02 per share in fourth-quarter 2023, missing the Zacks Consensus Estimate of $5.26. In the year-ago period, the company reported an adjusted loss of 7 cents per share.Total revenues in the reported quarter rose 4% year over year to $1.01 billion. Sales of Xywav, Epidiolex and Rylaze drove the upside. Total revenues were in line with the Zacks Consensus Estimate. Per management, this was the first time where the company achieved a billion dollars i ...

For the quarter ended December 2023, Jazz Pharmaceuticals (JAZZ) reported revenue of $1.01 billion, up 4.1% over the same period last year. EPS came in at $5.02, compared to -$0.07 in the year-ago quarter.The reported revenue represents a surprise of +0.37% over the Zacks Consensus Estimate of $1.01 billion. With the consensus EPS estimate being $5.26, the EPS surprise was -4.56%.While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to dete ...

Jazz Pharmaceuticals (JAZZ) came out with quarterly earnings of $5.02 per share, missing the Zacks Consensus Estimate of $5.26 per share. This compares to loss of $0.07 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of -4.56%. A quarter ago, it was expected that this drugmaker would post earnings of $4.90 per share when it actually produced earnings of $4.84, delivering a surprise of -1.22%.Over the last four quarters, the compa ...

Non-GAAP Net Leverage Ratio based on non-GAAP Adjusted EBITDA1 Reconciliation of GAAP net income to Non-GAAP Adjusted EBITDA1 (calculated in accordance with the Company's Credit Agreement) and the Calculation of NonGAAP Net Leverage Ratio | --- | --- | |--------------------------------------------------------------------|--------------------| | In millions (unaudited) | LTM Ended 12/31/23 | | GAAP net income 415 | | | Interest expense, net | 289 | | Income tax benefit (120) | | | Depreciation and amortizati ...